On March 31, 2026, Biogen Inc. announced its plan to merge with Apellis Pharmaceuticals, offering $41.00 per share plus potential additional payments of $4.00 based on sales milestones. This acquisition will allow Apellis to become a wholly owned subsidiary of Biogen.